You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

What Impact Does Convalescent Plasma Have on Blood Cancers and COVID-19?

  • Authors: News Author: M. Alexander Otto, MMS, PA; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 7/30/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 7/30/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists/medical oncologists, infectious disease clinicians, family medicine/primary care clinicians, internists, nurses, pharmacists, and other members of the healthcare team for patients with blood cancers and COVID-19.

The goal of this activity is to describe the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19 from a retrospective, multi-institutional cohort study, using data collected between March 17, 2020, and January 21, 2021 from the COVID-19 and Cancer Consortium registry with propensity score matching.

Upon completion of this activity, participants will:

  • Describe the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19, according to a retrospective, multi-institutional cohort study
  • Determine clinical implications of the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19, according to a retrospective, multi-institutional cohort study
  • Outline implications for the healthcare team


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


News Author

  • M. Alexander Otto, MMS, PA

    Freelance writer, Medscape

    Disclosures

    Disclosure: M. Alexander Otto, MMS, PA, has disclosed no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor/CME Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLCdesignates this continuing education activity for 0.25 contact hour(s) ( 0.025 CEUs) (Universal Activity Number: JA0007105-0000-21-429-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

What Impact Does Convalescent Plasma Have on Blood Cancers and COVID-19?

Authors: News Author: M. Alexander Otto, MMS, PA; CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 7/30/2021

Valid for credit through: 7/30/2022

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to COVID-19 vaccines may be provided in this activity to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.

Clinical Context

Antibody-based immunity plays an important role in vaccine-associated prevention of and recovery from SARS-CoV-2 infection. Hematologic cancers are linked to humoral and cellular immunity defects that may increase risk for adverse COVID-19 outcomes.

Study Synopsis and Perspective

A strong case for the routine use of convalescent plasma for patients with blood cancer who are hospitalized with COVID-19 is made by the results from a new study published in JAMA Oncology.[1]

Patients with blood cancer are at a particularly high risk for severe complications from COVID-19 because the cancer and its treatment short-circuit patients' ability to make antibodies to fight off infection. Convalescent plasma, obtained from people who have had COVID-19 and have recovered, provides such patients with antibodies.

The approach was useful during the Spanish flu pandemic in 1918, as well as during the more recent severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus pandemics.

The team conducted the study after "hearing physicians around the country report remarkable clinical improvements," said investigator Jeffrey Henderson, MD, PhD, associate professor of medicine and molecular microbiology at Washington University in St Louis, St Louis, Missouri, in a statement.

"I have seen one of my own patients with blood cancer quickly improve after receiving convalescent plasma," Henderson said. "Similar stories... suggested that a formal study" was in order.

The investigators analyzed data from 70 institutions in the United States that were participating in the COVID-19 and Cancer Consortium registry.

They pulled the records of 143 patients with hematologic malignancies who received convalescent plasma while hospitalized for COVID-19, and they compared the 30-day all-cause mortality with 823 hospitalized patients who did not receive the plasma. Among the plasma recipients, 19 patients (13.3%) died within 30 days of being diagnosed with COVID-19 vs 204 (24.8%) in the control group, which translated to a 40% reduction in the risk for death after controlling for confounders. After propensity matching, the reduction in the risk for death was 48%.

In an analysis that was limited to 338 patients who were admitted to the intensive care unit (ICU) for respiratory and other complications, 30-day mortality was 15.8% in the plasma group vs 46.9% in the control patients, which translated to a 60% drop in risk on propensity matching.

Among 227 patients who were placed on ventilators, 30-day mortality was 17.8% with convalescent plasma vs 53.3% without: a 68% reduction in risk on propensity matching.

"As with any observational study, causality cannot be inferred from these findings, but rather these findings can be viewed as contributing to the accumulating evidence regarding survival benefit with convalescent plasma treatment in patients with COVID-19 illness," said investigators led by Michael Thompson, MD, PhD, a medical oncologist and hematologist at Advocate Aurora Health in Milwaukee, Wisconsin.

"Our findings, along with other similar cases not in this database, support using convalescent plasma to improve survival in these patients," he said in a press release.[2]

Bridging the Gap

The findings fill "a major knowledge gap, as most studies on convalescent plasma" include few patients with cancer, commented Gregory Calip, PharmD, PhD, a hematology/oncology epidemiologist and biostatistician at Flatiron Health, in New York, New York, and colleagues in an accompanying editorial.[3]

Despite the limitations of retrospective data, "the consistent directionality and significance of the effect estimates reported is encouraging," the editorialists wrote. "Determining a causal treatment effect of convalescent plasma will ultimately require an appropriately designed clinical trial."

Plasma Patients Were Sicker

Among the study limits, it is not known how many transfusions of convalescent plasma each individual received, exactly when they received transfusions during their hospitalization, and how the transfusions were timed with respect to the patients' cancer treatments. Another unknown is the antibody levels of the transfused plasma.

Convalescent plasma recipients were considerably sicker than control patients; however, with more sepsis and respiratory complications. They were also more likely to have chronic lymphocytic leukemia. In such patients, COVID-19 is associated with a particularly bad prognosis. These patients are more likely to receive corticosteroids and the antiviral remdesivir.

There was a worry that thrombosis and acute kidney failure would be more prevalent among the plasma group because of the transfusions, but that did not turn out to be the case. On the other hand, the slightly higher rate of heart failure in the plasma group (7% vs < 3.5% on propensity matching), probably from volume overload, does bear watching, the investigators said.

The patients were treated from March 2020 to January 2021. It is likely most of the patients received plasma through the FDA's Expanded Access Program and subsequent emergency use authorization.

The mean age of the patients was 65 ± 15 years, and slightly more than half were men. Multiple myeloma was the most common cancer diagnosis, accounting for about 20% of cases.

The study was funded by the National Institutes of Health and others. Several investigators have disclosed ties to industry, but none were related to this study. The editorialists were employed by Flatiron Health, which is owned by Roche.

Study Highlights

  • This retrospective cohort study used data collected between March 17, 2020, and January 21, 2021 from the COVID-19 and Cancer Consortium registry, with propensity score matching to assess 966 patients with hematologic cancers who were hospitalized for COVID-19.
  • Mean age was 65 ± 15 years; 539 (55.8%) were male.
  • 143 convalescent plasma recipients were compared with 823 untreated control patients.
  • Convalescent plasma treatment was associated with improved 30-day mortality (HR = 0.6 [95% CI: 0.37, 0.97]) after adjustment for potential confounding factors.
  • Propensity score matching did not abolish the significance of this association (HR = 0.52 [95% CI: 0.29, 0.92]).
  • Among 338 patients admitted to the ICU, mortality was significantly lower in convalescent plasma recipients than in nonrecipients (HR for propensity score-matched comparison = 0.4 [95% CI: 0.2, 0.8]).
  • Among 227 patients requiring mechanical ventilation, convalescent plasma recipients had significantly lower mortality than nonrecipients (HR for propensity score-matched comparison = 0.32 [95% CI: 0.14, 0.72]).
  • The investigators concluded that giving convalescent plasma to patients with hematologic cancers and COVID-19 offered a potential survival benefit, with significantly improved 30-day mortality overall and in subgroups requiring ICU admission or mechanical ventilation, even after propensity score matching.
  • If prospective clinical trials confirm these findings, convalescent plasma would be the first COVID-19 intervention with a survival benefit in this vulnerable population.
  • The findings add to growing evidence for efficacy of convalescent plasma treatment in patients with primary or secondary immunodeficiency, including patients subjected to profound immunosuppression from hematopoietic stem cell transplant (HSCT).
  • The underlying mechanisms are likely multifactorial, include reduced viral load via enhanced clearance, fewer secondary bacterial and fungal infections, neutralization of inflammatory cytokines that could trigger a hyperinflammatory immune response, and temporizing until the innate immune system generates additional humoral and cell-mediated responses after recovering from myelosuppressive or lymphodepleting anticancer therapy.
  • The convalescent plasma group had better survival but more sepsis and respiratory complications, likely reflecting greater SARS-CoV-2 infection severity, although treatment complications cannot be completely excluded.
  • Adverse effects of protein-rich infusions may include thromboses, kidney injury, and volume overload, but both groups had low rates of thromboses and similar rates of acute kidney injury.
  • Still, rate of congestive heart failure with convalescent plasma was low (7%) but higher than in control participants (< 3.5%), which should be studied further in larger cohorts.
  • Study limitations include retrospective design precluding causal inferences, possible unmeasured confounding, and differences in blood cancer type and stage between recipients and control participants, all of which would be expected to cause worse outcomes in the recipients whereas the opposite occurred.
  • Prospective randomized trials of convalescent plasma in patients with hematologic cancers should further examine administration timing and consideration of repeated dosing.

Clinical Implications

  • Giving convalescent plasma to patients with hematologic cancers and COVID-19 offered a potential survival benefit, with significantly improved 30-day mortality overall and in subgroups, even after propensity score matching.
  • If prospective clinical trials confirm these findings, convalescent plasma would be the first COVID-19 intervention with a survival benefit in this vulnerable population.
  • Implications for the Healthcare Team: The findings add to growing evidence for efficacy of convalescent plasma treatment in patients with primary or secondary immunodeficiency, including patients subjected to profound immunosuppression from HSCT.

 

Earn Credit

  • Print